CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis

BACKGROUND AND AIMS: Alemtuzumab is a humanized monoclonal antibody that depletes CD52-bearing B and T lymphocytes. Clinical trials defined that systemic administration of alemtuzumab reduces disease severity in the relapsing–remitting phase of multiple sclerosis (MS). However, its efficacy in progr...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ther Adv Chronic Dis
Päätekijät: Bogie, Jeroen FJ, Grajchen, Elien, Wouters, Elien, Broux, Bieke, Stinissen, Piet, Van Wijmeersch, Bart, Hendriks, Jerome JA
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: SAGE Publications 2020
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7443992/
https://ncbi.nlm.nih.gov/pubmed/32913622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622320947378
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia